Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment

The current study aims to investigate the neurodevelopment of premature infants after intravitreal injections of bevacizumab (IVB) for the treatment of retinopathy of prematurity (ROP) up to the age of 2 years. The study design was retrospective observational case series conducted at an institutiona...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2016-01, Vol.11 (1), p.e0148019-e0148019
Hauptverfasser:	Lien, Reyin, Yu, Mu-Hsien, Hsu, Kuang-Hung, Liao, Pei-Ju, Chen, Yen-Po, Lai, Chi-Chun, Wu, Wei-Chi
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Bevacizumab Bevacizumab - administration & dosage Bevacizumab - adverse effects Bevacizumab - therapeutic use Biology and Life Sciences Birth weight Care and treatment Child Development - drug effects Child, Preschool Complications and side effects Developmental neurology Diabetic retinopathy Dosage and administration Drug therapy Engineering and Technology Epidemiology Hospitals Humans Immunotherapy Infant Infant, Extremely Low Birth Weight Infant, Newborn Infants Intellectual Disability - etiology Intravitreal Injections Laboratories Laser Therapy - adverse effects Lasers Medicine Medicine and Health Sciences Monoclonal antibodies Neurodevelopment Newborn babies Patient outcomes Patients Pediatrics People and Places Psychomotor Disorders - etiology Retina Retinopathy Retinopathy of prematurity Retinopathy of Prematurity - drug therapy Retinopathy of Prematurity - therapy Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!